Month: April 2022

CAMBRIDGE, Mass., April 05, 2022 (GLOBE NEWSWIRE) — Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today announced that its management team will participate in the following virtual conferences in April.Needham Healthcare Conference 2022Company Presentation by Chief Financial Officer Jeff Trigilio, Wednesday, April 13, 2022, 8:00 a.m. EDTCanaccord Genuity Horizons in Oncology Virtual ConferenceFireside Chat with Chief Executive Officer Nadim Ahmed, Thursday, April 14, 2022, 2:00 p.m. EDTLive webcasts of the Needham conference presentation and Canaccord Genuity conference fireside chat will be available via the Events section of the Company’s investor relations website at https://investors.cullinanoncology.com/news-events/events. Management...

LAS VEGAS, April 05, 2022 (GLOBE NEWSWIRE) — Live Ventures Incorporated (Nasdaq: LIVE), a diversified holding company, today announced that it repurchased 65,668 shares of common stock at an average price of $31.72 per share during its fiscal 2022 second quarter ended March 31, 2022. “We believe that our strategic focus on acquiring businesses that maximize stockholder value also gives us the ability and opportunity to look inwardly at our own Company to increase that value further,” commented Jon Isaac, President and CEO of Live Ventures. “Management firmly believes our stock repurchases represent long-term value for our stockholders.” On February 20, 2018, the Company announced a $10.0 million common stock repurchase plan. The Company has repurchased 484,138 shares of its common stock for approximately $5.4 million, representing...

Total revenues up 185% on annualized pace for more than $3.5 million for calendar 2022 driven by triple-digit growth across all segments TAMPA, FL, April 05, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – B2Digital Incorporated (the “Company” or “B2Digital”) (OTCMKTS:BTDG), the premier development league for mixed martial arts (“MMA”), is pleased to report unaudited performance metrics for the three and twelve months ended March 31, 2022, including total revenue growth of 185% year over year, which puts the Company on an annualized pace for more than $3.5 million in revenues in calendar year 2022, driven by triple-digit growth across all operating segments. Note: The following numbers represent unaudited preliminary data subject to potential revision in future financial reporting. Highlights for Twelve Months Ended March 31, 2022 (unaudited)...

Interim analysis performed with initial 150 U.S. patient samples enrolled in its prospective multicenter trial for the Unyvero UTI panel – Clinical Trial to be continued without any changes Reproducibility Study successfully completed prior to start of enrollment Clinical performance evaluation aims at a subsequent FDA submissionROCKVILLE, Md., April 05, 2022 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today that, following the successful completion of a reproducibility study earlier this year, it has now unblinded and analyzed a limited data set comprising of the first 150 prospectively enrolled U.S. patient samples. Clinical trial enrollment continues at...

CAMBRIDGE, Mass., April 05, 2022 (GLOBE NEWSWIRE) — Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Monday, April 11th at 11:00 a.m. ET. A live webcast of the presentation will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be available there for 30 days following the event. About Generation BioGeneration Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases. The company’s non-viral genetic medicine platform incorporates a novel DNA construct...